Daily Archives: July 21, 2020

The Russia Report who paid for Brexit? – TheArticle

Posted: July 21, 2020 at 12:50 pm

8.4 million it was the biggest ever political donation in British history, and made by an insurance salesman made uneasy by immigration and who opposed Britains membership of the European Union. Arron Banks gave this enormous sum of money to the 2016 Brexit campaign.

If that money came direct from Bankss bank account, then it was perfectly legal. (Banks has not been found to have breached electoral law). Foreign donations to elections and referendum campaigns have to be declared and identified. One of the biggest failures of the 1997 Labour government was not to adopt clear laws limiting political donations. Britain failed to ban donations by rich individuals or rich trade unions who want to buy influence.

Instead money continues to flow into political parties from the super rich, in exchange for access, peerages, and contracts.

Bankss close associations with the Russian government are not disputed. His own published accounts of his involvement in the Brexit campaign recorded meetings with the Russian ambassador Alexander Yakovenko, a close Putin associate. A Russian spy, Alexander Udod, was tasked with getting close to Nigel Farage, Ukip and Aaron Banks. Udod was expelled from the UK in 2018 following the attempted murder of Sergei Skripal in Salisbury.

The Skripal killer squad came from the GRU, the Russian military intelligence agency, headed up to 2016 by Igor Sergun. He was a strong advocate of Brexit, not from any reasons of taking back control or other anti-EU arguments advanced over many years by British politicians and journalists of right and left but simply because Putin intenselydisliked the role of the EU as a supra-national body which imposed sanctions on Russia after Putins invasion and annexation of Crimea.

Putin also disliked the EU Commissions competition directorate using EU law to stop Gazproms monopolistic practices in EU energy supply chains. Putins foreign policy is easily summed up. Russia up. America down. Europe out.

Putin had funded other anti-EU politicians like Marine le Pen in France, the Alternative fr Deutschland in Germany and the anti-EU Lega party of Matteo Salvini in Italy. In a sense this was no more than the continuation of a long-standing Russian practice since the 1920s of providing money for politicians and organisations which sympathised with Russian foreign policy objectives.

In evidence to the House of Commons Select Committee on Culture, Media and Sport, Banks and his associate, Andy Wigmore, denied any Russian connection.

Banks had been in Moscow and at least three business deals were offered at the Russian embassy or by Russian agents to the pair. The Russian ambassador and the spy Udod were invited to parties hosted by Banks.

The Electoral Commission did refer Banks to the National Crime Agency but Theresa May did not order the intelligence agencies help provide evidence. She refused to accept that any question mark might be placed over the very narrow win for Brexit when 36 per cent of the total registered electorate voted to leave the EU. Jeremy Corbyn has been a life-long opponent of EU membership and had voted against every EU treaty in the House of Commons since 1983.

With the arrival of Boris Johnson and a 100 per cent Brexit cabinet, the political establishment began to instinctively retreat from the notion that Russia may have influenced Brexit. Labours new leader, Sir Keir Starmer, also wants to shut down Brexit, believing that to challenge it would alienate Labour Red Wall voters who voted out in 2016.

In a new bookGoing Dark, Julia Ebner, a researcher at Londons Institute for Strategic Dialogue, reports on Russias Internet Research Agency, a Putin trolling operation that reached one in three Americans between 2015 and 2017 when Putin tried to get Trump elected. The Internet Research Agency set up 3,841 fake twitter accounts to pump out Kremlin lines on Trump and also Brexit. The Russian state-controlled TV station, RT, and linked news agency, Sputnik, based in in Edinburgh, provided endless platforms for anti-EU commentators, economists and politicians.

Banks may have gone too far with the chutzpah of his latest demand that he be allowed to see and challenge the suppressed Russia report that the Intelligence and Security Committee of the House of Commons produced last year, and which is released today. Johnson delayed publication but after the farce of his failed efforts to impose Chris Grayling as ISC Chair, we will now get to read it. The ISC Chair is Julian Lewis, a pro-Brexit Tory MP who has spent his political life seeking to expose the baleful Russian interference in democratic politics.

In the end Banks will survive as it was his legal right to give money to a political campaign. The fate of Brexit will be settled not by uncovering the origins of that 8.4 million, but on whether in 12 or 24 months time Brexit has brought us freedom, as the Brexiters always claimed it would, or whether we are left out in the cold.

Read more from the original source:

The Russia Report who paid for Brexit? - TheArticle

Posted in Brexit | Comments Off on The Russia Report who paid for Brexit? – TheArticle

Brexit will split financial markets, says Bank of England appointee – Reuters

Posted: at 12:50 pm

LONDON (Reuters) - Brexit will make markets less efficient but it wont be disastrous for Britains economy, an appointee to the Bank of Englands Financial Policy Committee (FPC) said on Monday.

FILE PHOTO: A small toy figure is seen in front of a Brexit logo in this illustration picture, March 30, 2019. REUTERS/Dado Ruvic/Illustration

Britain left the European Union in January, with transition arrangements that afford continued full access to the bloc ending in December.

Jonathan Hall told the Treasury Select Committee that Brexit represented a longer term risk of increased fragmentation and complexity in financial services.

This would increase friction costs for the economy, the supervisory burden, Hall said in a questionnaire he completed for the lawmakers.

Faced with an economy slammed by the COVID-19 crisis, Hall, a former Goldman Sachs banker, is due to start a three-year term on the FPC, a body set up after regulators failed to spot the last financial crisis coming a decade ago.

Britains financial sector is quite different in size and complexity compared with its European peers, Hall told the online meeting.

Future direct EU access for financial firms in Britain will hinge on Britain remaining equivalent or aligned with rules in Europe, but Hall said Britain cant be a rule taker.

Its very important that the UK does remain the regulator for the financial market in the UK, he said.

Britains banks, some of whom needed rescuing by taxpayers in the last crisis, were in good shape when the COVID-19 shock hit markets in March, he said.

It was so far, so good and there is no evidence that tougher capital rules brought in after the last crisis were restricting the ability of banks to lend to help businesses recover from the impact of COVID, Hall said.

Britain is looking at ways for insurers, pension funds and others to invest in firms struggling to repay loans taken out during the pandemic.

You can imagine some kind of closed-end fund that has a very diversified pool of small and medium sized businesses. But does the public sector need to do anything to help that along given this needs to move faster? Hall said.

(This story replaces Hall quote in paragraph 3 on fragmentation after BOE clarified it referred to clearing houses with new paragraph 3 and 4 from a questionnaire to lawmakers)

Reporting by Huw Jones; Editing by Andrew Heavens, Ken Ferris and Alison Williams

Original post:

Brexit will split financial markets, says Bank of England appointee - Reuters

Posted in Brexit | Comments Off on Brexit will split financial markets, says Bank of England appointee – Reuters

Alister Jack: ‘No threat’ to devolved power in post-Brexit laws – BBC News

Posted: at 12:50 pm

Media playback is unsupported on your device

Claims that Holyrood powers are under threat by post-Brexit legislation are "absolute scaremongering", the Scottish Secretary has said.

Alister Jack told BBC Scotland plans for a UK "internal market" amounted to a "power surge" and not a "power grab".

The proposals have been set out in a white paper, with legislation to follow later in the year.

Scottish Constitutional Affairs Secretary Mike Russell said any assurances from the UK were "not true".

Plans for how a UK-wide "internal market" will operate after the country leaves the EU were published earlier in the week.

UK Business Secretary Alok Sharma said the move would see "the biggest transfer of powers in the history of devolution".

But the Scottish government has said the plan would "strip power" from the Scottish Parliament.

Speaking on BBC Scotland's Sunday Politics programme, Mr Jack said the objections raised by Mr Russell were a "confected red herring".

He said there was "absolutely no threat" to Scottish government policies like free university tuition or alcohol minimum pricing.

"There is not a single power being taken away from Holyrood or any of the other devolved administrations and when challenged in parliament this week, they couldn't come up with a single power they're losing," he said.

"This is absolutely a power surge for them, not a power grab."

Much of the debate over powers has focused on food standards and whether chlorinated chicken would ever be sold in the UK.

But Mr Jack said this was "not going to happen".

"Chlorinated chicken can't be sold in the UK. Nor can hormone-induced beef. We're quite clear about that. They are illegal products," he said.

"We're going to bring all the EU food standards into UK domestic law at the end of this year in the Withdrawal Act. And then we intend to increase our food production standards and our animal welfare standards which are already the highest in Europe."

Mr Jack told the BBC that the only future changes would be to improve food standards and not "diminish" them.

He added: "Were it ever to come to pass that a future government did something on food standards that didn't satisfy the other devolved administrations first of all there would be a bill to go through the UK Parliament on that trade deal and then there would be consent motions sought from the other administrations."

However, Mr Russell said he had "no doubt" that under the current proposals chlorinated chicken could be sold in Scotland, even if the Scottish Parliament did not want it.

Speaking earlier on the programme, he said the proposals were there because the UK wanted to be able to do "bad trade deals" with other countries as they were the "only trade deals left to them".

"To do so they want to make sure that neither the Scottish Parliament or the Welsh Parliament or the Northern Irish Parliament can interfere with that," he said.

"That won't just be bad for consumers, it'll be very bad for business. It will put Scottish businesses out of business if they go ahead."

Mr Russell said he had heard many assurances in the past from the UK government but they had "come to nothing".

View post:

Alister Jack: 'No threat' to devolved power in post-Brexit laws - BBC News

Posted in Brexit | Comments Off on Alister Jack: ‘No threat’ to devolved power in post-Brexit laws – BBC News

The UK Government is playing the oldest trick in the book with Brexit – The National

Posted: at 12:50 pm

MACHIAVELLI is more of a moralist than we recognise. Everyone can run off his bon mots about fear and power, but no one bothers to recall his underlying warning-fear the public; you need them. A heavy-handed rule will only get you so far. Do not undertake actions that will offend the sensibilities of society. It is only better to be feared than loved because you cannot supply "freebies" forever.

And the latest "Brexit transition" videos are a case and point. They're hokey and rife with hawkish gibberish about "taking back control" and "unleashing" our potential. After 40 years, the good times are being ripped away and replaced with empty rhetoric about "significant opportunities".

Why are they needed at all? Finally, the Brexiteers realise what Remainers knew all along: paperwork for holidays to Spain, roaming charges and snail-pace airport queues are more pressing than bargain bucket notions "sovereignty".

READ MORE:UK government damned over lack of action over Russian interference

The UK Government is playing the oldest trick in the book with how it paints Brexit. Machiavelli knew leaders and governments could be saved or ruined by ideas of "us" and "them". He understood identity politics and how people are vicious in packs when there's a political purpose. The government is igniting a faux collective crisis to burn away the memory of what Brexit it.

Governments need the people; we seldom need them. History is replete with the names for how they've cultivated and fostered it - nationalism, patriotism, manifest destiny, revanchism, irredentism, empire: always, continually, cyclically "us", and "them".

International Relations has evolved as a field of study to explain power politics. Classical Realismfamously purports the international "system" is a continuance of human nature - fearful, reactionary and shattered along identity lines. Higher notions of "idealism" are utterly perfunctory to questions of survival.

Brexit is viscerally anathema because it goes against the grain of that self-interest. Not only are we giving up the benefits of international cooperation that make us feel safe, but we're also giving up opportunities for our children. If we're not at war or dealing with real economic challenges, then "national survival" is the argument of tyrants: you're against "us" if you're not playing for the "team". Look over there at those Europeans holding "us" back. Look further still at those dangers to "us".

READ MORE:Trade Bill: Tories reject effort to keep NHS off negotiating table

It's utterly arrogant to imply "nasty" nationalisms and arguments over race, ethnicity, language and history are a cliche of the Balkans. What we call citizenship is another name for gang warfare in a world of competing interests. For Aristotle, human beings are political animals, with an innate propensity to create and develop more complex communities. There are countless sociological, biological and anthropological arguments which state political affiliation is an inevitability of the human condition.

Political scientist Alexander Wendt famously built on this, claiming that the "anarchy" of international relations is all human-made. Political groups and states don't just exist before encountering the world; they evolve and change in response to other communities. Our operation within this system is a tactical choice between cooperation, war, defence - and peace.

All the softly spoken Brexit videos are designed to generate the kind of false unity that is both deluded and dangerous. The Downing Street countdown, the withdrawal coin, the calls for an independence day and now the latest media campaign are all designed to engender the people with a false consciousness that says it's counterproductive to go against it. Social media fact-checking, the contentiousness of the 2016 referendum (to say nothing of devolution and the national stay/leave splits) make it futile.

Worst of all, there's no excuse for it but to cover-up a monumental folly. We are neither at risk of annihilation or hemmed into a corner. Rightly or wrongly these kinds of national fictions are deployed throughout history to reshape the world. They're the beginnings of wars, the start of revolutions.

Brexit isn't even that cerebral. It's neither clever nor brave, ambitious nor bold. We must, must see these adverts, these campaigns for the nightmare they are. There's only an ideological illusion that a pyrrhic nationalism is a freedom from - well, freedom from what, exactly?

The biggest sin we can ever let come to pass is accepting it is unpatriotic to criticise a government because it goes against national morale, national purpose or national unity. That is unequivocally the beginning of tyranny, and governance by diktat. And that is the real lesson in all of Machiavelli's writings.

Alastair Stewart is a public affairs consultant with Orbit Communications. He regularly writes about politics and history with a particular interest in the life of Winston Churchill. Follow him on Twitter at@agjstewart

Go here to read the rest:

The UK Government is playing the oldest trick in the book with Brexit - The National

Posted in Brexit | Comments Off on The UK Government is playing the oldest trick in the book with Brexit – The National

Indirect Nonhealth Care Costs Drive Total Costs in Psoriatic Arthritis and Psoriasis – AJMC.com Managed Markets Network

Posted: at 12:48 pm

Psoriatic arthritis and psoriasis have high economic burdens and the total annual costs were similar between the 2 diseases, but the combination of both yielded the highest costs, according to an abstract published at the European League Against Rheumatism annual meeting.

The researchers analyzed 318 patients with psoriasis (n = 196), PsA (n = 43), or both (n = 79) in the COEPSO (Evaluation of Costs in patients with Psoriatic Disease) trial, an observational, retrospective, cross-sectional study in 22 Spanish centers from February 2017 to February 2018.

The authors obtained information from the year prior to the study on direct nonhealth care services (including social services, home care, and private health and nonhealth professionals), as well as indirect and total costs (direct nonhealth care and indirect costs) related to the disease. They calculated out-of-pocket costs, which were specified directly by the patients, and loss of productivity costs, which were gauged by the average salaries for the occupation specific by the patients.

Patients with both psoriasis and PsA had higher annual total costs than patients who only had 1 disease (75.5% higher than patients with psoriasis and 60.9% higher than patients with PsA). However, the total costs for patients with psoriasis and PsA were similar.

The average annual total cost per patient was 1042.71 ($1186.64) for psoriasis, 1137.84 ($1294.90) for PsA, and 1830.26 ($2082.89) for both. The breakdown of direct nonhealth care costs vs indirect costs were:

PsA and [psoriasis] have proved to be diseases with a high economic burden, and the total costs were mainly driven by direct non-healthcare costs, the authors concluded.

Reference

Vincente E, Castaeda S, Llamas Velasco M, et al. Cost of illness in patients with psoriasis and psoriatic arthritis. COEPSO Study. Presented at: EULAR 2020; June 3-6, 2020; Abstract OP0262-HPR. https://ard.bmj.com/content/79/Suppl_1/164.2

Read the original post:
Indirect Nonhealth Care Costs Drive Total Costs in Psoriatic Arthritis and Psoriasis - AJMC.com Managed Markets Network

Posted in Psoriasis | Comments Off on Indirect Nonhealth Care Costs Drive Total Costs in Psoriatic Arthritis and Psoriasis – AJMC.com Managed Markets Network

Analyzing Impacts Of COVID-19 On Psoriasis Market Effects, Aftermath And Forecast To 2026 – Cole of Duty

Posted: at 12:48 pm

The global Psoriasis market focuses on encompassing major statistical evidence for the Psoriasis industry as it offers our readers a value addition on guiding them in encountering the obstacles surrounding the market. A comprehensive addition of several factors such as global distribution, manufacturers, market size, and market factors that affect the global contributions are reported in the study. In addition the Psoriasis study also shifts its attention with an in-depth competitive landscape, defined growth opportunities, market share coupled with product type and applications, key companies responsible for the production, and utilized strategies are also marked.

This intelligence and 2026 forecasts Psoriasis industry report further exhibits a pattern of analyzing previous data sources gathered from reliable sources and sets a precedented growth trajectory for the Psoriasis market. The report also focuses on a comprehensive market revenue streams along with growth patterns, analytics focused on market trends, and the overall volume of the market.

Moreover, the Psoriasis report describes the market division based on various parameters and attributes that are based on geographical distribution, product types, applications, etc. The market segmentation clarifies further regional distribution for the Psoriasis market, business trends, potential revenue sources, and upcoming market opportunities.

Download PDF Sample of Psoriasis Market report @ https://hongchunresearch.com/request-a-sample/40648

Key players in the global Psoriasis market covered in Chapter 4:, Celgene Corporation, Takeda Pharmaceutical Company Limited, Pfizer Inc., Stiefel Laboratories Inc., Amgen Inc., Biogen Idec, Novartis AG, Eli Lilly and Company, Johnson and Johnson (Janssen Biotech Inc.), AbbVie Inc.

In Chapter 11 and 13.3, on the basis of types, the Psoriasis market from 2015 to 2026 is primarily split into:, Systemic, Phototherapy, Topical Treatment, Others

In Chapter 12 and 13.4, on the basis of applications, the Psoriasis market from 2015 to 2026 covers:, Injectable, Tropical, Oral

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:, North America (Covered in Chapter 6 and 13), United States, Canada, Mexico, Europe (Covered in Chapter 7 and 13), Germany, UK, France, Italy, Spain, Russia, Others, Asia-Pacific (Covered in Chapter 8 and 13), China, Japan, South Korea, Australia, India, Southeast Asia, Others, Middle East and Africa (Covered in Chapter 9 and 13), Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Others, South America (Covered in Chapter 10 and 13), Brazil, Argentina, Columbia, Chile, Others

The Psoriasis market study further highlights the segmentation of the Psoriasis industry on a global distribution. The report focuses on regions of North America, Europe, Asia, and the Rest of the World in terms of developing business trends, preferred market channels, investment feasibility, long term investments, and environmental analysis. The Psoriasis report also calls attention to investigate product capacity, product price, profit streams, supply to demand ratio, production and market growth rate, and a projected growth forecast.

In addition, the Psoriasis market study also covers several factors such as market status, key market trends, growth forecast, and growth opportunities. Furthermore, we analyze the challenges faced by the Psoriasis market in terms of global and regional basis. The study also encompasses a number of opportunities and emerging trends which are considered by considering their impact on the global scale in acquiring a majority of the market share.

The study encompasses a variety of analytical resources such as SWOT analysis and Porters Five Forces analysis coupled with primary and secondary research methodologies. It covers all the bases surrounding the Psoriasis industry as it explores the competitive nature of the market complete with a regional analysis.

Brief about Psoriasis Market Report with [emailprotected] https://hongchunresearch.com/report/psoriasis-market-40648

Some Point of Table of Content:

Chapter One: Report Overview

Chapter Two: Global Market Growth Trends

Chapter Three: Value Chain of Psoriasis Market

Chapter Four: Players Profiles

Chapter Five: Global Psoriasis Market Analysis by Regions

Chapter Six: North America Psoriasis Market Analysis by Countries

Chapter Seven: Europe Psoriasis Market Analysis by Countries

Chapter Eight: Asia-Pacific Psoriasis Market Analysis by Countries

Chapter Nine: Middle East and Africa Psoriasis Market Analysis by Countries

Chapter Ten: South America Psoriasis Market Analysis by Countries

Chapter Eleven: Global Psoriasis Market Segment by Types

Chapter Twelve: Global Psoriasis Market Segment by Applications12.1 Global Psoriasis Sales, Revenue and Market Share by Applications (2015-2020)12.1.1 Global Psoriasis Sales and Market Share by Applications (2015-2020)12.1.2 Global Psoriasis Revenue and Market Share by Applications (2015-2020)12.2 Injectable Sales, Revenue and Growth Rate (2015-2020)12.3 Tropical Sales, Revenue and Growth Rate (2015-2020)12.4 Oral Sales, Revenue and Growth Rate (2015-2020)

Chapter Thirteen: Psoriasis Market Forecast by Regions (2020-2026) continued

Check [emailprotected] https://hongchunresearch.com/check-discount/40648

List of tablesList of Tables and FiguresTable Global Psoriasis Market Size Growth Rate by Type (2020-2026)Figure Global Psoriasis Market Share by Type in 2019 & 2026Figure Systemic FeaturesFigure Phototherapy FeaturesFigure Topical Treatment FeaturesFigure Others FeaturesTable Global Psoriasis Market Size Growth by Application (2020-2026)Figure Global Psoriasis Market Share by Application in 2019 & 2026Figure Injectable DescriptionFigure Tropical DescriptionFigure Oral DescriptionFigure Global COVID-19 Status OverviewTable Influence of COVID-19 Outbreak on Psoriasis Industry DevelopmentTable SWOT AnalysisFigure Porters Five Forces AnalysisFigure Global Psoriasis Market Size and Growth Rate 2015-2026Table Industry NewsTable Industry PoliciesFigure Value Chain Status of PsoriasisFigure Production Process of PsoriasisFigure Manufacturing Cost Structure of PsoriasisFigure Major Company Analysis (by Business Distribution Base, by Product Type)Table Downstream Major Customer Analysis (by Region)Table Celgene Corporation ProfileTable Celgene Corporation Production, Value, Price, Gross Margin 2015-2020Table Takeda Pharmaceutical Company Limited ProfileTable Takeda Pharmaceutical Company Limited Production, Value, Price, Gross Margin 2015-2020Table Pfizer Inc. ProfileTable Pfizer Inc. Production, Value, Price, Gross Margin 2015-2020Table Stiefel Laboratories Inc. ProfileTable Stiefel Laboratories Inc. Production, Value, Price, Gross Margin 2015-2020Table Amgen Inc. ProfileTable Amgen Inc. Production, Value, Price, Gross Margin 2015-2020Table Biogen Idec ProfileTable Biogen Idec Production, Value, Price, Gross Margin 2015-2020Table Novartis AG ProfileTable Novartis AG Production, Value, Price, Gross Margin 2015-2020Table Eli Lilly and Company ProfileTable Eli Lilly and Company Production, Value, Price, Gross Margin 2015-2020Table Johnson and Johnson (Janssen Biotech Inc.) ProfileTable Johnson and Johnson (Janssen Biotech Inc.) Production, Value, Price, Gross Margin 2015-2020Table AbbVie Inc. ProfileTable AbbVie Inc. Production, Value, Price, Gross Margin 2015-2020Figure Global Psoriasis Sales and Growth Rate (2015-2020)Figure Global Psoriasis Revenue ($) and Growth (2015-2020)Table Global Psoriasis Sales by Regions (2015-2020)Table Global Psoriasis Sales Market Share by Regions (2015-2020)Table Global Psoriasis Revenue ($) by Regions (2015-2020)Table Global Psoriasis Revenue Market Share by Regions (2015-2020)Table Global Psoriasis Revenue Market Share by Regions in 2015Table Global Psoriasis Revenue Market Share by Regions in 2019Figure North America Psoriasis Sales and Growth Rate (2015-2020)Figure Europe Psoriasis Sales and Growth Rate (2015-2020)Figure Asia-Pacific Psoriasis Sales and Growth Rate (2015-2020)Figure Middle East and Africa Psoriasis Sales and Growth Rate (2015-2020)Figure South America Psoriasis Sales and Growth Rate (2015-2020)Figure North America Psoriasis Revenue ($) and Growth (2015-2020)Table North America Psoriasis Sales by Countries (2015-2020)Table North America Psoriasis Sales Market Share by Countries (2015-2020)Figure North America Psoriasis Sales Market Share by Countries in 2015Figure North America Psoriasis Sales Market Share by Countries in 2019Table North America Psoriasis Revenue ($) by Countries (2015-2020)Table North America Psoriasis Revenue Market Share by Countries (2015-2020)Figure North America Psoriasis Revenue Market Share by Countries in 2015Figure North America Psoriasis Revenue Market Share by Countries in 2019Figure United States Psoriasis Sales and Growth Rate (2015-2020)Figure Canada Psoriasis Sales and Growth Rate (2015-2020)Figure Mexico Psoriasis Sales and Growth (2015-2020)Figure Europe Psoriasis Revenue ($) Growth (2015-2020)Table Europe Psoriasis Sales by Countries (2015-2020)Table Europe Psoriasis Sales Market Share by Countries (2015-2020)Figure Europe Psoriasis Sales Market Share by Countries in 2015Figure Europe Psoriasis Sales Market Share by Countries in 2019Table Europe Psoriasis Revenue ($) by Countries (2015-2020)Table Europe Psoriasis Revenue Market Share by Countries (2015-2020)Figure Europe Psoriasis Revenue Market Share by Countries in 2015Figure Europe Psoriasis Revenue Market Share by Countries in 2019Figure Germany Psoriasis Sales and Growth Rate (2015-2020)Figure UK Psoriasis Sales and Growth Rate (2015-2020)Figure France Psoriasis Sales and Growth Rate (2015-2020)Figure Italy Psoriasis Sales and Growth Rate (2015-2020)Figure Spain Psoriasis Sales and Growth Rate (2015-2020)Figure Russia Psoriasis Sales and Growth Rate (2015-2020)Figure Asia-Pacific Psoriasis Revenue ($) and Growth (2015-2020)Table Asia-Pacific Psoriasis Sales by Countries (2015-2020)Table Asia-Pacific Psoriasis Sales Market Share by Countries (2015-2020)Figure Asia-Pacific Psoriasis Sales Market Share by Countries in 2015Figure Asia-Pacific Psoriasis Sales Market Share by Countries in 2019Table Asia-Pacific Psoriasis Revenue ($) by Countries (2015-2020)Table Asia-Pacific Psoriasis Revenue Market Share by Countries (2015-2020)Figure Asia-Pacific Psoriasis Revenue Market Share by Countries in 2015Figure Asia-Pacific Psoriasis Revenue Market Share by Countries in 2019Figure China Psoriasis Sales and Growth Rate (2015-2020)Figure Japan Psoriasis Sales and Growth Rate (2015-2020)Figure South Korea Psoriasis Sales and Growth Rate (2015-2020)Figure Australia Psoriasis Sales and Growth Rate (2015-2020)Figure India Psoriasis Sales and Growth Rate (2015-2020)Figure Southeast Asia Psoriasis Sales and Growth Rate (2015-2020)Figure Middle East and Africa Psoriasis Revenue ($) and Growth (2015-2020) continued

About HongChun Research:HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details:Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

Go here to see the original:
Analyzing Impacts Of COVID-19 On Psoriasis Market Effects, Aftermath And Forecast To 2026 - Cole of Duty

Posted in Psoriasis | Comments Off on Analyzing Impacts Of COVID-19 On Psoriasis Market Effects, Aftermath And Forecast To 2026 – Cole of Duty

The Hindu Explains | Why is a psoriasis drug being used to treat COVID-19 patients? – The Hindu

Posted: at 12:48 pm

The story so far: On July 11, pharma major Biocon announced that it had received the approval of the Drugs Controller General of India (DCGI) to market Itolizumab for treatment of cytokine release syndrome (CRS) in moderate to severe acute respiratory distress syndrome patients due to COVID-19. Itolizumab is a monoclonal antibody which is used to treat acute psoriasis.

Monoclonal antibodies are proteins cloned in the lab to mimic antibodies produced by the immune system to counter an infection. They have their genesis in serum, the colourless constituent of blood that contains antibodies. These proteins bind to an antigen, the fragment of an infectious virus in the case of SARS-CoV-2, and either destroy it or block its action. In the case of COVID-19, there are yet no proven drugs to treat moderate or severe manifestations of the disease. Among the therapies being tested is convalescent plasma, which is a constituent of blood and recovered from those who have successfully fought the disease. This blood contains antibodies produced within a week or two of being infected. While plasma therapy involves injecting this entire antibody-soup into another sick patient, a monoclonal antibody can be made by isolating specific antibodies and multiplying them via various techniques. Isolating plasma and serum is laborious and time-consuming when it must be administered to every patient. However, since 1975, several techniques have been perfected that allow antibodies once isolated to be easily replicated. These are stored in vials and can be injected into patients.

Also read | Biocons COVID-19 drug tested on too few patients to reliably conclude on benefits, say experts

While eight in 10 of those infected by the disease recover with little more than a few days of cough and fever, about one in 10 can manifest severe systems of the disease irrespective of their age and medical history. Experts are not sure why, but have observed that many who died were victims of a cytokine storm when the immune system goes into overdrive to flush out the virus. Pro-inflammatory cytokines recruit a host of specialised immune system cells to neutralise antigens. However, these cytokines can aggravate inflammation and injury in lung cells as well as in several other organs. A challenge in treatment is how to prevent this over-reaction. One method is to use antibodies that can block a particular protein, called CD6. They are found on the surface of T-cells, a class of cells that are a central prong in the bodys defence system.

Experts say if this CD-6 is suppressed, it will prevent the T-cells from releasing a cytokine cascade and thus better regulate the immune system. There is also a lot of research going on in using such antibodies to prevent the replication of the virus. Since last month there have been reports from laboratories from nearly everywhere, reporting the presence of one or more antibodies that could be used to block the spike protein, the key the coronavirus uses to infiltrate lung cells and proliferate. Before monoclonal antibodies were roped into discussions surrounding COVID-19, research has focused on deriving the right kind of antibodies that specifically bind onto regions of interest. These underpin the design of cancer therapies or fixes for autoimmune diseases, rheumatoid arthritis or acute psoriasis.

Sometimes antibodies are known to help viral entry and replication in target cells which can worsen the disease. This is why they need careful evaluation.

Also read | No evidence yet that itolizumab, tocilizumab reduces deaths: ICMR head

Itolizumab is an approved drug for acute psoriasis since 2013 and has passed safety and efficacy trials for that disease in over 500 patients. However, independent experts have pointed out that the efficacy of the drug in treating COVID-caused Acute Respiratory Disease Syndrome has not been conclusively demonstrated because it has, as part of a clinical trial, only been tested on 30 patients. However, the drug has been approved by the DCGI for emergency use in the treatment of moderate to severely-ill patients as per the discretion of physicians. The DCGI also directed Biocon to conduct a phase-4 study it must monitor it for adverse reactions or side-effects after it has been administered in large groups of patients and report back to the authorities. Experts pointed out that the normal process for approving a drug includes a phase-3 trial, where the drugs safety and efficacy are first evaluated in the wider population. Officials at Biocon claim they plan to test the drug in the United States, Canada, Australia and New Zealand. Several doctors, at a press conference organised by Biocon, said their patients had benefitted from the drug but mostly when they were yet to reach a stage before requiring ventilators or external oxygen support. The drug cost a little under 8,000 for every vial. Generally, four vials are necessary for treatment, company officials said.

You have reached your limit for free articles this month.

To get full access, please subscribe.

Already have an account ? Sign in

Show Less Plan

Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.

Move smoothly between articles as our pages load instantly.

Enjoy reading as many articles as you wish without any limitations.

A one-stop-shop for seeing the latest updates, and managing your preferences.

A select list of articles that match your interests and tastes.

We brief you on the latest and most important developments, three times a day.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

See the original post here:
The Hindu Explains | Why is a psoriasis drug being used to treat COVID-19 patients? - The Hindu

Posted in Psoriasis | Comments Off on The Hindu Explains | Why is a psoriasis drug being used to treat COVID-19 patients? – The Hindu

UNION therapeutics announces acquisition of PDE4i compound class from LEO Pharma with oral lead candidate (orismilast) in Phase 2 – BioSpace

Posted: at 12:48 pm

HELLERUP, Denmark, July 21, 2020 /PRNewswire/ -- UNION therapeutics A/S ("UNION") today announced the completion of a transaction with LEO Pharma A/S (LEO Pharma) to acquire the global rights for the LEO PDE4 inhibitor compound series to be re-named UNI500.

UNI500 is a series of phosphodiesterase type 4 (PDE4) inhibitors that were discovered by LEO Pharma. LEO Pharma has been developing candidates from this series from discovery into Phase 2 in psoriasis (orismilast, oral) and atopic dermatitis (orismilast, topical) and in both indications demonstrated superior effect over placebo in randomized, double-blinded, placebo-controlled clinical studies.

"The acquisition of the PDE4 inhibitor compound series is perfectly aligned with UNION's vision to build a sustainable pharmaceutical company and it complements our current clinical activities in immuno-dermatology. The acquisition substantially accelerates our growth trajectory and enables synergies at organizational, financial, and commercial levels. Above and beyond that, UNION considers compounds from the PDE4 inhibitor compound series to have best-in-class potential for the treatment of psoriasis and other immune-dermatological disorders, with an overarching aim to address unmet medical needs", said Rasmus Toft-Kehler, Chief Executive Officer of UNION.

Morten Sommer, Chief Scientific Officer, of UNION explains "Orismilast has demonstrated promising effects in clinical studies suggesting that it could become an attractive oral treatment option for patients with psoriasis and other immune-dermatological disorders. Our ambition, based on demonstrated potency levels, is to develop orismilast as a best-in-class PDE4 inhibitor across multiple immune-related diseases. As a next step, UNION will finalize formulation efforts with orismilast and simultaneously evaluate priority indications for clinical advancement".

Thorsten Thormann, Vice President, Global Research at LEO Pharma added "LEO Pharma has been working very closely with the UNION team and have been impressed with their approach and professionalism in dermatological drug development. Accordingly, when the strategic decision was taken to divest the LEO PDE4 inhibitor compound series and orismilast, UNION was an obvious partner of choice for LEO Pharma. We look forward to seeing the program moving forward for the benefit of patients in need of new treatment options".

Under the agreement, UNION will pay upfront, development and commercial milestones of up to 200 million USD, plus low single-digit royalties on sales. As part of the transaction, LEO Pharma also becomes a minority shareholder in UNION therapeutics.

About UNION therapeutics A/SUNION therapeutics A/S is a privately held, clinical stage, pharmaceutical company dedicated to the development of novel treatments for inflammatory and infectious diseases. The company is working on two complementary chemistry classes spanning immunology and microbiology and has three candidates in clinical development. UNION is headquartered in Hellerup (Denmark) and managed by an experienced team across Europe and USA.

About LEO Pharma A/SThe company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries.

ContactsMorten BoesenChief Financial OfficerTel: +45 2381 5487Email: info@uniontherapeutics.com

JW CommunicationsJulia WilsonTel: +44 781 8430877Email: communications@uniontherapeutics.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/union-therapeutics/r/union-therapeutics-announces-acquisition-of-pde4i-compound-class-from-leo-pharma-with-oral-lead-cand,c3157569

The following files are available for download:

View original content:http://www.prnewswire.com/news-releases/union-therapeutics-announces-acquisition-of-pde4i-compound-class-from-leo-pharma-with-oral-lead-candidate-orismilast-in-phase-2-301096733.html

SOURCE UNION therapeutics

Read more from the original source:
UNION therapeutics announces acquisition of PDE4i compound class from LEO Pharma with oral lead candidate (orismilast) in Phase 2 - BioSpace

Posted in Psoriasis | Comments Off on UNION therapeutics announces acquisition of PDE4i compound class from LEO Pharma with oral lead candidate (orismilast) in Phase 2 – BioSpace

Psoriasis and COVID-19: A narrative review with treatment considerations – DocWire News

Posted: at 12:48 pm

This article was originally published here

Dermatol Ther. 2020 Jun 17:e13858. doi: 10.1111/dth.13858. Online ahead of print.

ABSTRACT

Coronavirus disease (COVID-19) is a highly contagious respiratory infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 outbreak has been declared a pandemic by the World Health Organization on March 2020. The pandemic has affected the management of psoriasis not only for those who are under treatment but also for those who are about to begin a new therapy to control their disease. An increasing number of studies in the current literature have focused on the relationship between psoriasis and COVID-19 from different perspectives. This narrative review includes searching the PubMed and Web of Science databases using the keywords psoriasis, psoriatic arthritis, coronavirus, COVID-19, and SARS-CoV-2. The search was supplemented by manual searching of reference lists of included articles. A total of 11 relevant original investigations and 6 case studies was identified. The search was updated in May 2019. Due to the absence of randomized controlled trials, it is not likely to have a robust evidence-based approach to psoriasis management in the era of COVID-19. However, the current literature may provide some clues for safety considerations. Conventional immunosuppressive therapies such as methotrexate and cyclosporine, and anti-tumor necrosis factor agents should not be preferred due to increased risk of infection, especially in high-risk areas. The use of cyclosporine may pose additional risk due to the side effect of hypertension, which has been reported to be associated with susceptibility to severe COVID-19. Considering that the current literature has provided no conclusive evidence that biologics increase the risk of COVID-19, withdrawal of these agents should be reserved for patients with COVID-19 symptoms. The treatment approach should be personalized, considering the advantages and disadvantages for each case separately.

PMID:32686245 | DOI:10.1111/dth.13858

See the rest here:
Psoriasis and COVID-19: A narrative review with treatment considerations - DocWire News

Posted in Psoriasis | Comments Off on Psoriasis and COVID-19: A narrative review with treatment considerations – DocWire News

Explained: What is Itolizumab, newly cleared for Covid-19? – The Indian Express

Posted: at 12:48 pm

Written by Anuradha Mascarenhas | Pune | Updated: July 21, 2020 7:33:30 am The approval from the DCGI is based on the results from the conclusion of a randomised, controlled clinical trial at hospitals in Mumbai and New Delhi. (Express Photo/Praveen Khanna)

A repurposed drug, Itolizumab, is one of the newest treatments for Covid-19 approved in India. The Drug Controller General of India recently approved it as a novel biologic therapy for restricted emergency use. The decision has also sparked controversy because of the small size of the clinical trials, and because exemption has been granted from phase-III trials.

Itolizumab is an existing drug used for psoriasis, a chronic skin disease involving unregulated growth of some skin cells that develop into red patches mostly on knees and elbows, but also on some other parts of the body. The drug, developed by Bengaluru-based Biocon, was approved in 2013. It is considered safe and effective for the treatment of psoriasis.

Why was it approved for emergency use in Covid treatment?

The SARS-CoV-2 virus has been observed to induce an overreaction of the immune system, generating a large number of cytokines that can cause severe damage to the lungs and other organs, and, in the worst scenario, multi-organ failure and even death.

The approval from the DCGI is based on the results from the conclusion of a randomised, controlled clinical trial at hospitals in Mumbai and New Delhi. The study focused on the safety and efficacy of Itolizumab in preventing cardio-renal complications in Covid-19 patients who also have acute respiratory distress. The drug has been found to reduce these complications in such patients.

Also in Explained | Why community transmission no longer matters at this stage

Basically, the drug controls the hyper-activation of the immune system in response to SARS-CoV-2 virus and prevents morbidity and mortality related to the cytokine storm. The clinical trial showed that the drug is best administered in the pulmonary phase of the Covid-19 infection when the cytokine build up is starting and the patient is experiencing shortness of breath and exhibiting abnormal chest images. It prevents progression to the hyperinflammation phase (cytokine storm) and other complications like coagulation and organ failure, according to Dr Sandeep Athalye, Chief Medical Officer, Biocon Biologics.

The drug has been used over 80 patients in Cuba and off-label in over 150 cases. According to Dr Shashank Joshi, Dean, Indian College of Physicians, the most critical part is to know when to use the drug and it must be reserved for moderate to severe Covid cases with cytokine storm where oxygen requirements are rapidly going up. usually between the 8th day onwards of Covid infection.

What were the results of the trial?

The trial results showed a statistically significant advantage over the control group of patients, in one-month mortality rate. All the patients who were administered Itolizumab were weaned off oxygen by Day 30, and none needed ventilator support unlike the control group that did not get the drug. Some other inflammations commonly found in such patients were also suppressed, and these correlated well with clinical improvement in symptoms. Overall, the drug was found well-tolerated.

Express Explainedis now onTelegram. Clickhere to join our channel (@ieexplained)and stay updated with the latest

How large was the trial?

The trial had 20 participants given the drug along with supportive care and 10 others given only supportive care. All 20 patients on Itolizumab recovered while three of the other 10 patients died.

Public health experts and some doctors have used social media to question the sample size of the trial. When journalists raised this question at a virtual press conference, Kiran Mazumdar-Shaw, Executive Chairperson, Biocon, said Itolizumab has been approved in India and since the country is in a medical emergency, it was decided to go ahead with a clinical trial involving a cohort of 30 patients. She said the regulatory process was extremely robust and the scientific discussions on the trial was of a very high order.

The DCGI has also exempted the drug from phase III clinical trials and allowed phase IV trials (post-marketing surveillance). Itolizumab is not a new drug and was approved in India since 2013. We had done phase II and III trials, and got the approval. In the past seven years, its been used in psoriasis and we know how the mechanism works Biocon Biologics CMO Dr Athalye said. Company officials said they plan phase IV trials soon.

How much does it cost?

Each injection is presented as a 25mg/5ml solution, which costs Rs 7,950 per vial. Based on an average body weight of 60 kg, the therapy cost of a single dose comprising four vials is estimated at Rs 32,000 (MRP).

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Explained News, download Indian Express App.

The Indian Express (P) Ltd

Link:
Explained: What is Itolizumab, newly cleared for Covid-19? - The Indian Express

Posted in Psoriasis | Comments Off on Explained: What is Itolizumab, newly cleared for Covid-19? – The Indian Express